- FDA Feedback on Seralutinib Phase 3 Clinical Trial Received; Expected to Commence in the Second Half of 2023 - - Topline Data from TORREY Study Open-Label Extension Expected in Mid-2023 - - Enrollment in GB5121 Phase 1b/2 Clinical Trial in PCNSL Paused - - Cash, cash equivalents and marketable